Investment Thesis
AIM ImmunoTech is a pre-revenue biotech company with minimal cash generation, burning $2.7M quarterly against only $22K in revenue. With $5.8M cash reserves and negative operating cash flow, the company faces a critical runway crisis within 2-3 periods absent significant financing or revenue development.
Strengths
- Net loss improving 19.4% YoY indicating cost management efforts
- Cash position of $5.8M provides near-term operational runway
- EPS loss reduced 72.1% YoY suggesting dilution control
Risks
- Pre-revenue company burning $2.7M quarterly with only $22K in revenue creating imminent solvency crisis
- Dangerously tight current ratio of 1.01x and high debt-to-equity of 1.98x limit financial flexibility
- Cash runway of approximately 2-3 quarters at current burn rate without additional financing or revenue generation
Key Metrics to Watch
- Quarterly cash balance and burn rate trends
- Revenue and clinical pipeline progress updates
- Debt refinancing developments and capital raise announcements
Financial Metrics
Revenue
22.0K
Net Income
-3.0M
EPS (Diluted)
$-0.69
Free Cash Flow
-2.7M
Total Assets
8.6M
Cash
5.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-10,118.2%
Net Margin
-13,740.9%
ROE
-142.3%
ROA
-35.2%
FCF Margin
-12,440.9%
Balance Sheet & Liquidity
Current Ratio
1.01x
Quick Ratio
1.01x
Debt/Equity
1.98x
Debt/Assets
75.2%
Interest Coverage
-7.32x
Long-term Debt
4.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T07:37:20.814851 |
Data as of: 2026-03-31 |
Powered by Claude AI